{"id":18244,"date":"2026-08-19T09:24:49","date_gmt":"2026-08-19T09:24:49","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=case-study&p=18244"},"modified":"2026-08-19T10:18:24","modified_gmt":"2026-08-19T10:18:24","slug":"gdf15-gfral-assay-development-drug-discovery","status":"publish","type":"case-study","link":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/gdf15-gfral-assay-development-drug-discovery\/","title":{"rendered":"Development of a Multimodal Assay System for GDF15\/GFRAL Drug Discovery"},"content":{"rendered":"\n

Transforming Receptor Biology into a Screening-Ready Discovery Platform<\/strong><\/h2>\n\n\n\n

Successful drug discovery begins with a detailed understanding of target biology <\/a>and the signaling pathways that underpin disease. Translating this understanding into robust cellular models and screening assays is critical for identifying and progressing new therapeutics. For emerging targets, this requires more than assay development<\/a> alone. It demands cellular systems that accurately reproduce complex signaling biology while delivering the robustness required for screening, lead optimization <\/a>and characterization.<\/p>\n\n\n\n

This challenge was central to a program focused on the GDF15-GFRAL pathway, an emerging therapeutic target attracting significant interest in metabolic disease, obesity, cachexia and oncology. GDF15 signaling is mediated through binding to GFRAL, which subsequently recruits the RET co-receptor to activate downstream signaling pathways, including ERK (Figure 1). Successfully modelling this biology requires coordinated expression of multiple receptor components while maintaining functional coupling to intracellular signaling mechanisms, creating a significant challenge for cell line generation and assay development.<\/p>\n\n\n\n

\"GDF15
Figure 1. <\/strong>Schematic representation of GDF15-GFRAL-RET complex signaling pathway.<\/figcaption><\/figure>\n\n\n\n

To address these challenges, Sygnature Discovery combined expertise in cell line generation,<\/a> receptor pharmacology and assay development to establish a stable inducible GDF15-GFRAL-RET cellular platform and complementary assay formats that support both compound screening and pharmacological confirmation.<\/p>\n\n\n\n

Project Highlights:<\/strong><\/h4>\n\n\n\n